In 2009, we demonstrated that miR-205 directly targets HER3 in HER2+ breast cancer cell lines, leading to impairment of the Akt-mediated survival pathway, and improved responsiveness to TKI inhibitors such as Gefitinib and Lapatinib [23]. Here, ERBB3 is linked to breast carcinoma.